Table III.
Number of adverse events in patients.
| Toxicity | Total n (%) | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
|---|---|---|---|---|---|
| Anemia | 3 (7) | 3 (7%) | 0 | 0 | 0 |
| Neutrophil count decreased | 3 (7) | 2 (4%) | 1 (2%) | 0 | 0 |
| Transaminase elevation | 9 (20) | 8 (18%) | 0 | 1 (2%) | 0 |
| Hyperbilirubinemia | 4 (9) | 4 (9%) | 0 | 0 | 0 |
| Anorexia | 6 (14) | 6 (14%) | 0 | 0 | 0 |
| Malaise | 5 (11) | 5 (11%) | 0 | 0 | 0 |
| Diarrhea | 8 (18) | 5 (11%) | 3 (7%) | 0 | 0 |
| Hand-foot skin reaction | 5 (11) | 5 (11%) | 0 | 0 | 0 |
| Sensory neuropathy | 2 (4) | 2 (4%) | 0 | 0 | 0 |
| Skin hyperpigmentation | 3 (12) | 3 (12%) | 0 | 0 | 0 |
| Stomatitis | 4 (9) | 4 (9%) | 0 | 0 | 0 |
| Colonic perforation | 1 (2) | 0 | 0 | 0 | 1 (2%) |
| Vaccination site reaction | 39 (88) | 31 (70%) | 8 (18%) | 0 | 0 |